The University of Oxford has launched a study to assess the safety and immune response of the COVID vaccine it has developed with AstraZeneca Plc in children for the first time, Report informs referring to
The new mid-stage trial will determine whether the vaccine is effective for people between the ages of 6 and 17.
Around 300 volunteers will be enrolled, and the first vaccinations are expected this month.
The two-dose Oxford/AstraZeneca vaccine has been hailed as a ‘vaccine for the world’ because it is cheaper and easier to distribute than some rivals.
AstraZeneca aims to produce 3 billion doses this year and aims to make over 200 million doses per month by April.